Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma
Open Access
- 1 March 2019
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 58 (5) , 707-712
Abstract
A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.Keywords
This publication has 12 references indexed in Scilit:
- Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphomaBlood Cancer Journal, 2015
- Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working PartyLeukemia, 2014
- Hepatosplenic γδ T-cell Lymphoma: An OverviewClinical Lymphoma Myeloma and Leukemia, 2013
- Gemcitabine-based combination regimen in patients with peripheral T-cell lymphomaMedical Oncology, 2012
- Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumLeukemia & Lymphoma, 2010
- Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeAnnals of Oncology, 2009
- Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatmentAnnals of Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patientsBlood, 2003
- Cell cycle effects of gemcitabineInternational Journal of Cancer, 2001